SUPERNUS PHARMACEUTICALS, INC. (SUPN) — SEC Filings

Latest SEC filings for SUPERNUS PHARMACEUTICALS, INC. (SUPN), explained in plain English.

Sentiment Overview: 1 bullish, 2 bearish, 46 neutral, 1 mixed

Recent Filings (50)

• Supernus Pharmaceuticals Completes Asset Acquisition — 8-K · 2026-04-07T17:25:26-04:00 [neutral] Risk: medium
  On April 1, 2026, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement and completed the acquisition of assets. The filing details the co
• Supernus Swings to Loss Amid Sage Acquisition, ZURZUVAE Launch — 10-Q · 2025-11-06T00:00:00.000Z [bearish] Risk: high
  SUPERNUS PHARMACEUTICALS, INC. reported a significant net loss of $45.1 million for the three months ended September 30, 2025, a sharp decline from a net income
• 8-K Filing — 8-K · 2025-11-04T00:00:00.000Z [neutral]
• Supernus Pharmaceuticals Files 8-K on Financials — 8-K · 2025-10-21T00:00:00.000Z [neutral] Risk: low
  On October 21, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
• Supernus Pharmaceuticals Files 8-K/A Amendment — 8-K/A · 2025-10-16T00:00:00.000Z [neutral] Risk: low
  Supernus Pharmaceuticals, Inc. filed an 8-K/A on October 16, 2025, to amend its previous filing related to the period ending July 31, 2025. The amendment concer
• Supernus Q2 Revenue Jumps 21%, Net Income Dips Amid Rising Costs — 10-Q · 2025-08-05T00:00:00.000Z [mixed] Risk: medium
  SUPERNUS PHARMACEUTICALS, INC. reported a significant increase in total revenues for the three and six months ended June 30, 2025. Total revenues for the second
• Supernus Pharmaceuticals Reports Officer and Director Changes — 8-K · 2025-08-04T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed an 8-K on August 4, 2025, reporting changes effective June 16, 2025. The filing details the departure of directors or certa
• Supernus Pharmaceuticals Completes Asset Acquisition — 8-K · 2025-07-31T00:00:00.000Z [neutral] Risk: medium
  On July 30, 2025, Supernus Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from Impel Pharmaceuticals Inc. for an undisclose
• Supernus Pharmaceuticals Files 8-K on Financials — 8-K · 2025-07-22T00:00:00.000Z [neutral] Risk: low
  On July 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its results of operations and financial condition. The filing includes financial
• Supernus Pharmaceuticals Files 8-K for Shareholder Vote & Exhibits — 8-K · 2025-06-17T00:00:00.000Z [neutral] Risk: low
  On June 16, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report to announce the submission of matters to a vote of security holders and to file financial s
• Supernus Pharmaceuticals Files 8-K — 8-K · 2025-06-16T00:00:00.000Z [neutral] Risk: medium
  On June 13, 2025, Supernus Pharmaceuticals, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The
• Supernus Pharmaceuticals Files 8-K — 8-K · 2025-05-28T00:00:00.000Z [neutral] Risk: low
  On May 22, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No sp
• Supernus Pharmaceuticals Files Q1 2025 10-Q — 10-Q · 2025-05-06T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported its financial results for the first quarter of 2025. Ke
• Supernus Pharma Files Proxy Statement — DEF 14A · 2025-04-30T00:00:00.000Z [neutral] Risk: low
  Supernus Pharmaceuticals, Inc. filed its definitive proxy statement on April 30, 2025, for its annual meeting on June 16, 2025. The filing outlines the company'
• Supernus Pharmaceuticals Files 8-K on Financial Condition — 8-K · 2025-04-23T00:00:00.000Z [neutral] Risk: low
  On April 23, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing results of operations and financial condition. The filing does not contain speci
• Supernus Pharmaceuticals Files 2024 10-K — 10-K · 2025-02-25T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed its 2024 10-K on February 25, 2025, reporting on its fiscal year ending December 31, 2024. The company, headquartered in Ro
• Supernus Pharmaceuticals Files 8-K on Director Changes — 8-K · 2025-02-24T00:00:00.000Z [neutral] Risk: low
  On February 24, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing incl
• Supernus Pharmaceuticals Files 8-K — 8-K · 2025-02-18T00:00:00.000Z [neutral] Risk: low
  On February 18, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine co
• Supernus Pharmaceuticals Files 8-K on Financials — 8-K · 2025-02-11T00:00:00.000Z [neutral] Risk: low
  On February 11, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condit
• Supernus Pharmaceuticals Files 8-K Report — 8-K · 2025-02-04T00:00:00.000Z [neutral] Risk: low
  On February 4, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," i
• Supernus Pharmaceuticals Files 8-K — 8-K · 2025-01-27T00:00:00.000Z [neutral] Risk: low
  On January 27, 2025, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating routine cor
• Supernus Pharmaceuticals Files 8-K on Ethics Code and Exhibits — 8-K · 2024-12-20T00:00:00.000Z [neutral] Risk: low
  On December 19, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns amendments to the company's Code of Ethics and the inclu
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Supernus Pharmaceuticals Files Q3 2024 10-Q — 10-Q · 2024-11-04T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported royalty, license, and other revenue for the third q
• SC 13G/A Filing — SC 13G/A · 2024-11-01T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-10-31T00:00:00.000Z [neutral]
• Supernus Pharmaceuticals Files 8-K for Regulation FD Disclosure — 8-K · 2024-10-30T00:00:00.000Z [neutral] Risk: medium
  On October 30, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company is providing a Regulation FD Disclosure. No speci
• Supernus Pharmaceuticals Files 8-K on Financials — 8-K · 2024-10-21T00:00:00.000Z [neutral] Risk: low
  On October 21, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial conditi
• Supernus Pharmaceuticals Files 8-K — 8-K · 2024-10-17T00:00:00.000Z [neutral] Risk: low
  On October 17, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with a Regulatio
• Supernus Pharmaceuticals Files 8-K — 8-K · 2024-10-10T00:00:00.000Z [neutral] Risk: low
  On October 10, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific mater
• Supernus Pharmaceuticals Completes CNS Pharmaceuticals Acquisition — 8-K · 2024-08-19T00:00:00.000Z [bullish] Risk: medium
  On August 19, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing indicates that the company has completed its previously announced acquisition
• Supernus Pharma Q2 2024 10-Q Filed — 10-Q · 2024-08-06T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported royalty, license, and other revenue for the second quart
• Supernus Pharmaceuticals Files 8-K Report — 8-K · 2024-08-01T00:00:00.000Z [neutral] Risk: low
  On August 1, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily serves as a notification of an event and does not contain specific f
• Supernus Pharmaceuticals Files 8-K on Financials — 8-K · 2024-07-23T00:00:00.000Z [neutral] Risk: low
  On July 23, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report detailing its financial results and operations. The filing includes financial statements an
• Supernus Pharmaceuticals Files 8-K — 8-K · 2024-06-17T00:00:00.000Z [neutral] Risk: low
  Supernus Pharmaceuticals, Inc. filed an 8-K on June 14, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing
• Supernus Pharmaceuticals Files 8-K — 8-K · 2024-05-23T00:00:00.000Z [neutral] Risk: low
  Supernus Pharmaceuticals, Inc. filed an 8-K on May 23, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not
• Supernus Pharmaceuticals Files 8-K — 8-K · 2024-05-09T00:00:00.000Z [neutral] Risk: low
  On May 9, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating no major new eve
• Supernus Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · 2024-05-08T00:00:00.000Z [bearish] Risk: medium
  SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Revenue for the three months ended March 31, 2024, was $178.5
• Supernus Pharmaceuticals Announces 2024 Annual Meeting of Stockholders — DEF 14A · 2024-04-29T00:00:00.000Z [neutral] Risk: low
  SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. The 2024 Annual Meeting of Stockholders for Supernus Pha
• Supernus Pharmaceuticals Announces Board Changes — 8-K · 2024-04-24T00:00:00.000Z [neutral] Risk: low
  On April 22, 2024, Supernus Pharmaceuticals, Inc. announced changes to its Board of Directors, including the election of Dr. Elizabeth H. Shea and Mr. David M.
• Supernus Pharmaceuticals Files 8-K with Exhibits — 8-K · 2024-04-08T00:00:00.000Z [neutral] Risk: low
  On April 8, 2024, Supernus Pharmaceuticals, Inc. filed an 8-K report. The filing primarily concerns the submission of financial statements and exhibits, indicat
• Supernus Pharmaceuticals Reports Officer Compensation & Board Changes — 8-K · 2024-02-28T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed an 8-K on February 28, 2024, reporting events from February 22, 2024. The filing primarily concerns changes in compensatory
• Supernus Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · 2024-02-27T00:00:00.000Z [neutral] Risk: medium
  SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed a Annual Report (10-K) with the SEC on February 27, 2024. Supernus Pharmaceuticals, Inc. filed its annual report for
• Supernus Pharmaceuticals Reports Executive Changes and Compensation Arrangements — 8-K · 2024-02-21T00:00:00.000Z [neutral] Risk: low
  Supernus Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an event on February 14, 2024, concerning the departure or election of directors or
• SC 13G Filing — SC 13G · 2024-02-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-02-14T00:00:00.000Z [neutral]
• Supernus Files 8-K on Financial Results and Exhibits — 8-K · 2024-02-13T00:00:00.000Z [neutral] Risk: medium
  Supernus Pharmaceuticals, Inc. filed an 8-K Current Report with the SEC on February 13, 2024. This filing, with accession number 0001356576-24-000006, specifica
• SC 13G/A Filing — SC 13G/A · 2024-02-13T00:00:00.000Z [neutral]
• SUPN Files 8-K for 'Other Event'; Routine Admin Update — 8-K · 2024-02-05T00:00:00.000Z [neutral]
  Supernus Pharmaceuticals, Inc. filed an 8-K on February 5, 2024, to report an "Other Event." This filing primarily updates administrative details, confirming it
• BlackRock Amends Supernus Pharma Stake as of Dec 31, 2023 — SC 13G/A · 2024-01-19T00:00:00.000Z [neutral]
  BlackRock Inc. filed an amended SC 13G/A on January 19, 2024, indicating its ownership of Supernus Pharmaceuticals Inc. common stock as of December 31, 2023. Th